Publications by authors named "Thorsten Ruf"

Claim this Profile
E
Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
Nastya Kassir, David McDougall, Denison Kuruvilla, Sean Kim, Shaun Kumar, Thorsten Ruf

J Clin Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi, Makoto Nishio, Thorsten Ruf

N Engl J Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose alectinib for fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Thorsten Ruf

Contemp Oncol (Pozn)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomass partitioning and nutrient fluxes in and silage maize cropping systems.
Thorsten Ruf, Christoph Emmerling

Nutr Cycl Agroecosyst· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.
Nicolas Frey, Walter Bordogna, Bogdana Balas, Thorsten Ruf, Venice Archer

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Peter N Morcos, Katrijn Bogman, Stanislas Hubeaux, Carolina Sturm-Pellanda, Thorsten Ruf

Cancer Chemother Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Stefan Sturm, Darren Bentley, Paul Jordan, Fiona Russell-Yarde, Thorsten Ruf

J Cardiovasc Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Stefan Sturm, Michael Seiberling, Idelette Weick, Axel Paehler, Christoph Funk, Thorsten Ruf

Clin Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis